Marybeth McAfee, MA, GC, is Vice President of Community and Medical Affairs at the National Organization for Rare Disorders (NORD®), where she leads Medical Affairs, Community Engagement, Membership, Educational Initiatives, and Information Services. She also oversees NORD’s Rare Disease Centers of Excellence program, helping drive collaboration across patients, families, advocacy organizations, clinicians, researchers, and health systems to strengthen rare disease diagnosis, care, and readiness for research and clinical trials. Trained as a genetic counselor, Marybeth has spent most of her career in non-clinical roles focused on improving how people living with rare diseases find trusted information, specialists, and pathways to care. Before becoming Vice President, she served as NORD’s Director of Medical Affairs and helped launch and grow the NORD Rare Disease Centers of Excellence Network. Prior to joining NORD, she worked at the NIH’s Genetic and Rare Diseases Information Center (GARD) and led programs related to rare disease registries and patient-focused therapy development. Her background also includes genetics research at Harvard. Marybeth is especially passionate about building practical infrastructure that makes rare disease care more connected, equitable, and scalable, and about ensuring that patient and family perspectives inform work across the therapeutic development pathway.
This NORD-led spotlight session will begin with a structured presentation outlining the NORD Centers of Excellence program—its rationale, design principles, and role in strengthening rare disease care infrastructure. The presentation will focus on how standardized designation, accountability, and collaboration improve diagnosis, care coordination, and health system readiness.
Following the presentation, NORD will facilitate a brief discussion with select local Centers of Excellence representatives to highlight real-world implementation and early impact within health systems. Together, the session will demonstrate why care delivery infrastructure is an essential complement to therapeutic innovation, with implications for patient outcomes, access, and clinical trial readiness.